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ABSTRACT 
Autism Spectrum Disorder (ASD) defines a set of 
neurodevelopmental disorders characterized by persistent deficits in 
social communication and interaction, along with repetitive patterns of 
behavior. Symptoms generally appear in the early developmental 
period and cause significant impairment in individual and social 
functioning. In recent years the increased prevalence of ASD, along 
with the evidence of a significant link between autism and 
gastrointestinal (GI) disturbances, raised a special interest in exploring 
the reciprocal influences between gut and brain. Investigators 
highlighted the existence of a so-called “gut-brain axis”, empowering 
the hypothesis that GI abnormalities could trigger neuropsychiatric 
symptoms in ASD. Intestinal microbiota is thought to play a pivotal 
role in gut and systemic homeostasis, in CNS development, as well as 
in behavioral modulation and recurrent microbial imbalances have 
been shown in gut microbiota of autistic people. In this review we 
analyze current knowledge about intestinal microbiota and the 
relevance and role of dysbiosis in ASD. The most accredited theories 
about gut-brain interaction will be reviewed, along with current 
scientific evidence supporting the relationship between microbial 
imbalances and impairment of neurodevelopment. Finally, we will 
focus on the results of different therapeutic approaches in this context: 
administration of pre- and probiotics, antibiotics, fecal microbiota 
transplantation and special diets and dietary supplements.  
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INTRODUCTION 
Autism Spectrum Disorder (ASD) encompasses a wide range of 
conditions characterized by an impairment in neurodevelopment 
leading to persistent deficits in social communication and social 
interaction, along with repetitive patterns of behavior, interests and 
activities. Symptoms generally appear in the early developmental 
period and persist life-long causing significant impairment in 
individual and social functioning. The term “spectrum” refers to the 
wide variability of presentations. Indeed, in 2013 the Diagnostic and 
statistical manual of mental disorders (5th ed., DSM V) introduced 
this new definition to merge some previously separate entities: autism, 
Asperger's syndrome, childhood disintegrative disorder and a 
pervasive developmental disorder not otherwise specified. 
ASD is diagnosed in all racial, ethnic and socio-economic groups and 
it is three to four times more common in boys than in girls. A 
progressive increase of ASD prevalence has been reported worldwide 
over the last decades. Among US children a rise in prevalence from 
0.67% in 2000 to 1.47% in 2010 has been reported, with a plateau in 
2012 (1.46%). A recent large, nationwide population-based study 
reported an estimated ASD prevalence of 2.47% among US children 
and adolescents in 2014-2016, with no statistically significant increase 
over the 3 years.1 It is postulated that at least part of the previously 
reported increase in ASD prevalence could reflect the effects of 
expanded definitions of the disorder, increased public awareness and 
clinician referral, along with a probable true increase in risk factors. 
To date, the etiology still remains unknown. ASD is probably a 
multifactorial disorder, resulting from the interaction of 
environmental, immune, genetic and epigenetic factors. Various 
environmental risk factors have been suggested and are currently 
under investigation, including advanced parental age, pregnancy-
related complications, use of medications during pregnancy (e.g. 
valproate), pre- or postnatal exposure to chemicals (e.g. 
organophosphates and heavy metals), drugs or pollutants, viral 
infections and metabolic imbalances, along with the evidence of an 
important genetic influence, as demonstrated by a strong aggregation 
in identical twins.2,3 
Children with ASD are at increased risk for a broad spectrum of 
concomitant medical issues, the most prevalent being sleeping 
problems, epilepsy, immune dysregulation and gastro-intestinal (GI) 
disturbances. The co-occurrence of these disorders appears to be 
associated with more severe behavioral symptoms in the affected 
child.4 
The most commonly reported GI disturbances among ASD children 
are chronic constipation, abdominal pain, diarrhea, bloating, gastro-
esophageal reflux, disaccharidase deficiencies, as well as pathologic 
findings such as inflammation of the GI tract and abnormalities of the 
enteric nervous system.5 
According to a consensus report of 2010 the reported prevalence of GI 
disorders in ASD patients aged 1–18 years ranged from 9 to 91%.5 
This relevant heterogeneity may be explained by different 
methodological approaches and study designs, different criteria to 
define GI problems and also difficulties for ASD subjects to 
communicate their symptoms. A recent meta-analysis confirmed a 
higher prevalence of GI symptoms among ASD children compared to 
control peers.6  
GI comorbidities have raised increasing interest not only due to their 
frequency and secondary impact in worsening ASD behavioral 
problems, but also because of their possible primary role in 
contributing to the genesis of the neurodevelopmental disorder. 
Indeed anxiety problems, irritability, sleep disorders, self-injury and 
oppositional behaviors appear to be significantly more common 
among ASD children with GI symptoms, compared to peers without 
GI disturbances.7, 8 It seems plausible that behavioral problems could 
be triggered or exacerbated by GI distress. 
On the other hand recent theories propose gut dysregulation as a 
possible primary cause of disruption of the neurodevelopment process. 
This theories rely on the existence of a so-called “gut-brain axis”, a 
bidirectional complex network of communication between the central 
nervous system (CNS), the enteric nervous system (ENS) and the gut, 
that seems to play a key role in the physiological neurodevelopment. 
The exact mechanisms by which gut and brain reciprocally influence 
each other are still unclear. 
Several factors co-operate to the normal functioning of the gut-brain 
axis, among them: the integrity of the gut mucosal lining, the luminal 
enzymatic activity and the regular absorption of nutrients, the 
secretion of neurotransmitters and their precursors, as well as many 
other signaling molecules, cytokines and bacterial products. In this 
context the intestinal microbiota seems to play a key role in 
maintaining gut homeostasis and probably in preserving a normal gut-
brain inter-relation. These evidences led to focus research efforts on 
the putative pathophysiological relevance of dysbiosis in ASD.9, 10 
Dysbiosis is defined as any qualitative or quantitative change in the 
composition of resident microbial communities compared to the 
communities found in healthy individuals. 
The advances in DNA sequencing technologies have revolutionized 
the field of microbiomics, supplanting culture-based approaches and 
expanding investigational fields. Thanks to the amplification and 
sequencing of target microbial DNA regions and the more recent 
whole-genome shotgun sequencing techniques, investigators can 
identify the constituents of the microbiome, analyze their microbial 
genome, identify genetic variability and obtain taxonomic analysis. 
In this review we summarize current knowledge of intestinal 
microbiota and the role of dysbiosis in autism spectrum disorders. The 
most accredited theories about gut-brain interaction will be reviewed, 
along with current scientific evidence supporting the relationship 
between microbial imbalances and impairment of neurodevelopment. 
Finally, we will focus on the results of different therapeutic 
approaches that have been proposed to target gut dysregulation in 
ASD patients. 
MICROBIOTA: DEFINITION AND FUNCTIONS 
Humans are complex ecosystems, in which a large number of 
microorganisms live in symbiosis with the host. As a whole 
“superorganism”, our body is composed of 10% of human cells and 
90% of microbial cells, the latter populating almost every cutaneous 
and mucosal surface of the body. These microorganisms (mainly 
bacteria, but also viruses, fungi and archeas) constitute the human 
microbiota.11  
The most heavily colonized area of the human body is the digestive 
tract, particularly the colon. The whole genome of gut 
microorganisms, the so-called gut microbioma, comprises nearly 150 
times more genes than the human genome.  
The gut microbiota is composed by 1014 different bacteria, divided 
into 4 different phyla: Firmicutes, Bacteroidetes, Actinobacteria and 
Proteobacteria. Firmicutes and Bacteroidetes are the predominant 
phyla (60-75% and 30-40% of the gut microbiota, respectively).12  
The Firmicutes phylum is composed of Gram-positive bacteria 
(Lactobacillus, Enterococcus, Clostridium, Ruminococcus, 
Streptococcus, Staphylococcus); Bacteroidetes are Gram-negative 
bacteria such as Bacteroides and Prevotella.13 
Gut microbiota plays an important role in maintaining the homeostasis 
of the human body, contributing to several fundamental functions, 
such as fermentation of otherwise indigestible carbohydrates, 
hydrolysis of proteins into peptides and free amino acids, 
deconjugation of bile salts and synthesis of some vitamins (K and 
biotin). Moreover, it is essential for the development of the immune 
system and to keep an efficient immune control: bacterial metabolites 
stimulate the epithelial production of IgA, regulate cytokines 
synthesis, assure a balance between regulatory T cells and effector T 
lymphocytes and play a central role in maintaining the integrity of the 
intestinal barrier. For instance, germ-free (GF) mice display Peyer’s 
patches hypoplasia, depletion of intra-epithelial lymphocytes, reduced 
secretion of IgA and cytokines and decreased serum levels of 
immunoglobulins. These abnormalities can be reverted after 
colonization.12  
Moreover, growing evidences suggest that gut microbiota modulates 
CNS development and function, thus influencing human behavior and 
concurring to the pathogenesis of neuropsychiatric disorders, as 
discussed in greater detail hereunder. 
MICROBIOTA: DEVELOPMENT 
Human microbiota develops during the early phases of life, changes 
with breast/formula feeding and weaning and it achieves its definitive 
composition in the third year of life. 
In the past, the intrauterine environment was considered completely 
sterile. Recent evidence demonstrated the presence of bacteria in 
amniotic fluid, placenta, umbilical cord blood and meconium.14 
Bacterial composition is similar in placenta and meconium, thus 
suggesting a microbial transfer from mother to fetus via bloodstream 
and placenta.13  
Maternal stress and diet, prenatal infections and exposure to 
antibiotics can modify both mother’s and offspring’s gut microbiota. 
Gestational age and delivery mode highly influence infants’ gut 
microbial composition as well. Caesarean delivery exposes infants to 
mother's skin microbiota (dominated by Staphylococcus, 
Corynebacterium and Propionibacterium), whilst vaginally born 
infants harbor bacteria similar to their mothers’ fecal and vaginal 
microbiota (mainly Lactobacillus and Prevotella).14  
Additional modifications are induced by diet. Breast milk contains a 
great amount of Streptococci and Staphylococci and complex 
oligosaccharides that stimulate the growth of Staphylococci and 
Bifidobacteria.13 Breast-fed infants have different, more stable and 
uniform microbial populations when compared to the formula-fed 
ones.15 
Further changes occur after the introduction of solid food. The 
definitive composition of gut microbiota is achieved at the end of the 
third year of life, and tends to remain stable in adulthood: 60%-70% 
of microbiota remains unchanged throughout life.  
Intercurrent events like illnesses, diet modifications, infections and 
antibiotic treatments may cause imbalances in the intestinal 
microflora, potentially resulting in dysbiosis.14  
 
MICROBIOTA AND CNS DEVELOPMENT 
Gut microbiota and CNS evolve in parallel during fetal life and after 
birth, and several evidences suggest a fundamental role of the 
microflora in warranting a correct neurodevelopment. Deviances in 
gut microbiota composition have been linked to abnormalities in CNS 
development in different studies on animal models.  
For instance, multiple alterations in neurogenesis have been described 
in GF mice, resulting in abnormally increased synaptic maturation and 
myelination, as well as in volumetric changes in hippocampus and 
amigdala.13, 16 
Recent studies demonstrated an influence of microbiota on microglial 
maturation and blood-brain-barrier (BBB) permeability. Indeed, 
microglia displays an immature profile in GF mice, with a reduced 
ability to react to inflammatory stimuli, whilst a decreased expression 
of tight-junctions in the brain endothelium has been described, leading 
to increased BBB permeability. These abnormalities are reversed after 
administration of short-chain fatty acids (SCFA) or after gut 
colonization.16 
MICROBIOTA AND BEHAVIORAL CHANGES 
Dysregulation of gut microbiota can result not only in structural CNS 
abnormalities, but also in behavioral alterations, described both in 
animal models and humans.  
Various pre-natal and early life events have been related to imbalances 
in microbiota composition and concomitant behavioral changes. For 
example, exposure to non-absorbable antibiotics in early gestational 
age in rats caused reduction in social interactions and increased 
anxiety in offspring.17 In another study, the administration of non-
absorbable antibiotics to pregnant mice induced variations in 
microbiota composition in offspring, which, from a behavioral point 
of view, showed low locomotor activity.18 
In mice, a high-fat diet during pregnancy resulted in abnormalities of 
gut microbiota (particularly with a reduction of Lactobacillus reuteri) 
and reduced social interactions in offspring. Treatment with L. reuteri 
improved offspring’s sociability. Recently, obesity and diabetes 
mellitus in pregnant women have been linked to a higher risk of 
ASD.16, 19 
Concerning prenatal infections, immune activation during pregnancy 
has potentially severe outcomes on offspring behavior and 
neurodevelopment. Some studies found a correlation between  
prenatal infections and a higher risk of schizophrenia and ASD in 
humans. Based on these findings, rodent models of Maternal Immune 
Activation (MIA) were developed. MIA offspring show abnormal 
communication and sociability, repetitive behaviors and increased 
anxiety.20  
Hsiao et al. demonstrated microbiota alterations and higher gut 
permeability in MIA offspring. Treatment with Bacteroides fragilis 
corrected gut permeability, restored microbial composition and 
improved communicative behaviors.21  
Maternal separation is a typical model of early life stress employed in 
animal studies. In rats, early maternal separation induced higher 
plasma corticosterone levels (a common marker of stress), anxiety-
like behaviors, alterations in gut microbiota and functional GI 
symptoms.22 Treatment with Lactobacillus during maternal separation 
reduced corticosterone levels.23 In macaques, early maternal 
separation reduced levels of Lactobacillus in offspring’s gut 
microbiota and increased distress-related behaviors.24 
GF mice show various behavioral abnormalities, among them: 
exacerbated response to stress, reversed by reconstitution with 
Bifidobacterium infantis; and reduced social interactions, normalized 
after recolonization.25, 26 Conflicting results are reported by other 
authors, describing reduced anxiety in GF mice.27, 28 
Several data in animal models and humans suggest that probiotic and 
antibiotic administration can modify microbiota composition 
transiently or permanently, possibly resulting in behavioral changes.16  
GUT DYSBIOSIS AND ASD 
The evidence of the impact of dysbiosis on CNS raised interest in the 
analysis of gut microbiota in neurodevelopmental, psychiatric and 
neurodegenerative disorders: depression, anxiety, schizophrenia, 
Attention Deficit Hyperactivity Disorder (ADHD) and ASD; 
Parkinson’s and Alzheimer’s disease were also investigated in this 
context.  
Anecdotally, parents of children with regressive autism reported a 
relationship between the onset of neurobehavioral changes and 
repeated courses of antibiotics, followed by chronic diarrhea.29 
Moreover, different studies showed a higher frequency of antibiotic 
use in early life in children who later developed ASD.30 Therefore, the 
disruption of gut microbiota has been proposed as a potential 
contributory cause of ASD.  
Various studies have analyzed the microbiota composition in ASD 
suggesting several major abnormalities, but so far results are often 
conflicting, failing to generate a coherent picture. Other studies 
showed no differences in gut microbiota composition between 
children with ASD and their siblings, rejecting the hypothesis of a 
bacterial role in triggering or maintaining ASD. According to the 
authors, other explanations for the GI dysfunction in this population 
should be considered, including elevated levels of anxiety and self-
restricted diets.10  
A recent study showed a higher prevalence of small intestinal bacterial 
overgrowth (SIBO) in ASD patients compared to controls, associated 
to worse behavioral manifestations.31 SIBO consists in an increase in 
number and/or alteration in type of bacteria colonizing the small 
bowel. 
Large-scale studies, using standardized methodologies, are needed to 
overcome these conflicting results.  
Hereafter we summarize the main abnormalities of gut microbiota 
described in literature among ASD patients. 
Clostridium 
Investigations initially focused on the exploration of possible 
alterations in gut-populating Clostridium species, because of their 
known ability to produce potentially neurotoxic compounds. Finegold 
et al. (2002) demonstrated higher counts of Clostridium and 
Ruminococcus spp in children with autism; nevertheless these data 
were not confirmed in a subsequent study.32,33 
Song et al. demonstrated high abundance of a novel species of 
Clostridium (C. bolteae) in ASD patients and higher levels of 
clostridial cluster I e XI (which include toxin-producing clostridia), 
and decreased XIVab cluster.34,35    
Parracho et al. demonstrated higher levels of C. histolyticum in ASD 
patients, and higher levels of Clostridia were associated to the 
presence of GI symptoms.36 
Higher levels of Clostridia cluster I were confirmed by Tomova et 
al.37 
Bacteroidetes/Firmicutes ratio 
Finegold et al. (2010) described higher levels of Bacteroidetes in ASD 
patients, while Firmicutes were predominant in the control group.33  
Conversely, Tomova et al., Williams et al. and Strati et al. showed a 
lower Bacteroidetes/Firmicutes ratio in autistic children. A lower ratio 
was evidenced in patients with more severe GI symptoms.37-39 
Lactobacillus 
Adams et al. described higher levels of Lactobacillus spp in autistic 
children, data confirmed by Tomova et al.9,37 
Bifidobacter 
De Angelis et al. and Adams et al. showed lower levels of 
Bifidobacterium spp in ASD.9,40  
Desulfovibrio 
A role of Desulfovibrio in the pathogenesis of ASD has been 
suggested, mainly because of its ability to release lipopolysaccharides 
(LPS) and to produce potentially toxic metabolites like hydrogen 
sulphide.  
Finegold et al. (2010) described higher levels of Desulfovibrio in 
autistic subjects.33 These data were confirmed by Tomova et al., who 
described a relationship between Desulfovibrio levels and ASD 
symptoms and a significant decrease in Desulfovibrio levels after 
probiotic administration.37 
Sutterella  
Williams et al. (2012) described a higher prevalence of Sutterella 
species in GI biopsies of ASD patients with GI symptoms compared 
to non-autistic children with functional GI disorders.41 
Wang et al. and De Angelis et al. confirmed elevated levels of 
Sutterella in feces of ASD patients compared to neurotypical 
controls.40,42 
Fungi 
Yeast proliferation can lead to lower absorption of carbohydrates and 
higher release of ammonia and toxins, which are thought to contribute 
to autistic behaviors. Few studies have investigated the relationship 
between intestinal fungi and ASD.  Kantarcioglu et al. described a 
higher prevalence of yeasts in feces of ASD patients compared to 
controls, the most commonly isolated species being Candida albicans. 
These data were confirmed by Strati et al. and Iovene et al.38, 42 Iovene 
et al. found no relationship between GI symptoms and Candida levels 
in ASD patients.43 
 
DYSBIOSIS IN THE PATHOGENESIS OF ASD: PROPOSED 
MECHANISMS 
Brain and gut, including gut microbioma, communicate reciprocally 
by means of complex and not fully elucidated ways of signal 
transmission, including metabolic, neural, endocrine and immune 
pathways. In this context, different mechanisms have been proposed 
to explain the influence of gut dysbiosis on ASD pathogenesis or 
exacerbation. The absorption of microbial components or metabolites 
seems to play a pivotal role, probably fostered by the increased 
intestinal permeability described both in humans and animal models 
of ASD, the so-called “leaky gut syndrome”. 
Leaky gut syndrome 
The intestinal barrier is a selective and dynamic filter which regulates 
the absorption of nutrients from the lumen into the circulation and 
simultaneously prevents the penetration of pathogens or their 
metabolites. Recently, several studies have been investigating the 
intestinal permeability (IPT) in patients suffering from 
neurodevelopmental and psychiatric disorders, including ASD. 
IPT is generally evaluated by dosing the urinary excretion of two 
orally administered indigestible saccharides with different molecular 
size and absorption routes. One (usually lactulose) passes the 
intestinal barrier through paracellular pathways, mainly regulated by 
tight junctions, and in physiological conditions it is minimally 
absorbed (1%). The co-administered sugar (usually mannitol) uses the 
transcellular transport and its absorption is proportional to the small 
bowel surface and absorptive capacity. An increased urinary excretion 
of lactulose reflects a higher intestinal permeability, whereas an 
intestinal inflammation with mucosal damage results in a decreased 
mannitol absorption. Hence, a higher urinary lactulose/mannitol ratio 
reveals an increased IPT.  
In 1996, D’Eufemia et al. firstly demonstrated a high frequency of 
altered IPT in autistic children, mainly due to the increased lactulose 
recovery, thus suggesting mostly a damage of the tight junctions.44 An 
increase in IPT was subsequently confirmed by de Magistris et al., 
Iovene et al. and Horvath et al.43, 45, 46 
Fiorentino et al. described a reduction of barrier-forming tight junction 
components (Claudin-1, Occludin, Tricellulin) and an increase in 
pore-forming elements (Claudin-2, -10, -15) in duodenal biopsies of 
ASD patients compared to healthy controls, strengthening the 
hypothesis of an impaired intestinal barrier in autism. 
Conflicting results have been published in this field as well. Kushak et 
al., Robertson et al., Dalton et al., Kemperman et al. and Pusponegoro 
et al. failed to demonstrate an increased IPT in ASD children.47-51  
Several studies focused on the analysis of fecal calprotectin (FC) 
levels in ASD patients. FC is a protein synthetized by intestinal 
granulocytes. Higher calprotectin levels in feces indicate neutrophil 
migration and infiltration in the intestinal tract, thus it is commonly 
used as a marker of local inflammation in inflammatory bowel 
diseases. These investigations in ASD were aimed at evaluating if an 
increased IPT in autistic children could be related to intestinal 
inflammation. De Magistris et al. showed abnormal FC levels in 
24.6% of the autistic patients, but there was no correlation between 
IPT and FC values.45 Kushak et al. described no differences in FC 
values in ASD children compared to controls, data confirmed by 
Pusponegoro et al., Iovene et al., Fernell et al. and Babinska et al.43, 47, 
51-53 All together, these results coherently reject the hypothesis of an 
increased intestinal inflammation as a cause of higher IPT in autistic 
patients. 
Recently, other studies tried to evaluate if IPT variations could be 
explained by higher circulating levels of Zonulin. Zonulin is a protein 
which physiologically modulates IPT, inducing tight junction 
disassembly, by modifying protein-protein interaction. Several 
stimuli, including intestinal dysbiosis, can induce Zonulin synthesis, 
therefore influencing IPT. Esnafoglu et al. demonstrated higher levels 
of Zonulin in ASD patients compared to neurotypical controls, 
whereas no statistically significant difference was described by 
Józefczuk et al. Further studies are needed in this field, to assess the 
effective role of Zonulin in modulating IPT in ASD children and the 
potential usefulness of Zonulin inhibitors (such as larazotide acetate) 
in these patients.54, 55 
To summarize, whether IPT is increased or not in autism is still 
debatable, and the influence of the so-called “leaky gut syndrome” on 
ASD pathogenesis and symptoms has yet to be demonstrated. 
Cytokines and Lipopolysaccharides (LPS)  
Immune system appears to be an important factor intervening in gut-
brain intercommunication. Intestinal bacteria exert either pro- or anti-
inflammatory effects depending on the type of bacteria (pathogenic or 
commensal) and the type of immune response elicited (T helper cells 
or regulatory T cells). Hence pro- or anti-inflammatory cytokines are 
secreted and, apart from their local actions, they can reach the brain 
via the bloodstream and, in certain conditions, it is thought that they 
can pass the BBB and exert central actions.  
In detail, cytokine signaling seems to especially affect the 
hypothalamus, an area of the CNS where the BBB is deficient. Here 
pro-inflammatory cytokines such as IL-1 and IL-6 can activate the 
hypothalamic-pituitary-adrenal (HPA) axis, inducing cortisol release 
and activation of the stress system, that can in turn influence gut 
function.56 
GF mice show a higher elevation of plasma ACTH and corticosterone 
levels in response to stress, normalized by reconstitution.25 This 
evidence could be interpreted as an hyper-reactivity of the HPA axis, 
with amplified response to stress in GF mice. 
In ASD patients, increased levels of inflammatory cytokines have 
been reported and were associated to impaired social skills. Moreover, 
a marked neuroinflammation has been described in brain specimens of 
ASD individuals.29, 30 
Immune activation, with the production of inflammatory cytokines, 
can also be elicited by the translocation of LPS (a component of the 
cell wall of Gram-negative bacteria) through the intestinal wall into 
the systemic circulation. Some studies described elevated serum levels 
of LPS in ASD patients compared to healthy controls, and higher 
levels were associated to impaired social behavior, probably 
suggesting the role of inflammation and immune activation in 
promoting ASD.29, 30 
Hence, the correct balance in circulating levels of cytokines seems to 
be essential for CNS development and HPA axis normal response to 
stress: a higher systemic inflammation can alter this process, leading 
to neurodevelopmental disorders. 
Short-chain fatty acids (SCFA) 
Short-chain fatty acids (SCFA), including acetate, proprionate and 
butyrate, are produced by microbial fermentation of complex 
carbohydrates (e.g. resistant starch, inulin, pectin). They represent the 
primary energy source for colonocytes and play an essential role in 
maintaining the gut epithelial barrier by strengthening the tight 
junctions and stimulating the production of the mucus layer. They also 
regulate transepithelial transport, particularly of water and 
electrolytes, as well as intestinal motility and modulate the 
inflammatory state of the intestinal mucosa by stimulating the 
production of anti-inflammatory compounds. Furthermore SCFAs 
show an inhibitory effect on neutrophil migration, leading to 
limitation of the inflammatory processes.  
The demonstration of quantitative imbalances in SCFAs levels in 
ASD children would provide further indication for a role of dysbiosis 
in this neurodevelopmental disorder. Unfortunately there is conflicting 
evidence about this issue. Wang et al. found significantly increased 
levels of SCFAs in fecal samples from autistic children compared to 
controls, while another study by Adams et al. reported opposite 
results.9, 57 
De Angelis et al. found significantly lower levels of butyric, but not 
acetic or propionic acid, in ASD children.58 
Although SCFAs are known to have neuroactive properties, their 
exact role in ASD remains poorly understood. Butyrate can cross the 
BBB and is known to act as a histone deacetylase inhibitor, thus being 
able to modulate gene silencing and gene expression in the CNS. It is 
believed to play a role in the epigenetic pathways of transcriptional 
regulation of neurotransmission, particularly in the prefrontal cortex. 
The prefrontal cortex is an area of the CNS with primary roles in 
cognitive, emotional and social behaviors, frequently affected by 
morphological, transcriptional, and epigenetic dysregulation in autistic 
individuals.59  
Intraperitoneal administration of butyrate has been shown to improve 
social behavior and repetitive symptoms in a murine model of ASD59, 
whereas intra-cerebroventricular infusions of propionic acid induce 
autistic-like behaviors in rats.60 
Furthermore SCFAs seem to be involved in multiple pathways of 
neurodevelopment; for instance they regulate microglial maturation 
and activation, and oral treatment with SCFAs can rescue impaired 
microglial function in GF animals.61 
However, since the expression of SCFA receptors is low or absent in 
the brain61, some authors argue that these compounds are likely to 
have mainly indirect effects on the CNS, probably mediated by 
glucagon-like peptide-1 (GLP-1), a gut hormone with both 
neurotrophic and anti-inflammatory actions, or via the vagus nerve.62 
Further research is warranted to fully understand the role, if any, of 
SCFAs in ASD and other neurologic disorders. 
Glutamate, serotonin and other neurotransmitters 
The aminoacid glutamate acts as an excitatory neurotransmitter and an 
excess of glutamate is known to induce neuronal cell death in the 
CNS. In the gut glutamate can also be produced from the hydrolysis of 
proteins and peptides by proteolytic bacteria (e.g. Clostridium and 
Bacteroides). High levels of glutamate have been found in fecal and 
blood samples of children with ASD compared to healthy controls and 
this hyperglutamatergic state has been suggested to play a pivotal role 
in the pathophysiology of autism.7, 58, 63 
Besides glutamate, gut microbiota can indirectly regulate many other 
central neurotransmitters, such as serotonin, by altering the levels of 
precursors. Serotonin is known to be involved in the modulation of 
anxiety, stress responses, reward, and social behavior. 
Bifidobacterium infantis has been shown to increase plasma 
tryptophan levels, thus empowering serotoninergic transmission in the 
CNS.64 Reduced levels of Bifidobacterium spp have been 
demonstrated in autistic patients, supporting their protective role in 
CNS development and functioning. In a metabolomics study the 
colonization of GF mice by gut microbiota determined an almost 
three-fold increase in plasma serotonin levels.65 In animal models, a 
defective serotoninergic neurotransmission has been linked to the 
pathogenesis of several behavioral abnormalities and CNS structural 
changes. Mutant mice for genes involved in the serotonin signaling or 
in its degradation show abnormal serotoninergic transmission and 
display social deficits.66 Furthermore, mice manipulation leading to 
excess serotonin clearance during early stages of neurodevelopment 
has been shown to influence neuronal migration, axonal projections, 
and synapse development.67  
Interestingly, synthesis and direct release of various neurotransmitters 
from bacteria has been reported: specific strains of Lactobacillus and 
Bifidobacterium spp can produce γ-aminobutyric acid (GABA); 
Escherichia, Bacillus and Saccharomyces spp can produce 
noradrenaline; Candida, Streptococcus, Escherichia and Enterococcus 
spp can produce serotonin; Bacillus can produce dopamine and 
Lactobacillus acetylcholine.56 These neurotransmitters, once 
synthesized in the gut, cannot cross the BBB, but their central effects 
are likely to be mediated by an action on the ENS via the vagus nerve. 
Oxytocin 
Oxytocin is a neuropeptide secreted from the hypothalamus and 
implicated in the regulation of various social behaviors in mammals 
such as emotional bonding, maternal care, affiliation and social 
attachment. Reduced oxytocin blood levels, genetic variants of the 
oxytocin receptor and mutations of proteins involved in oxytocin 
release have been demonstrated in ASD individuals, leading to the 
hypothesis that oxytocin could play a role in modulating autistic 
behaviors and thus suggesting a potential therapeutic effect of 
oxytocin administration.68 
Intriguingly, a recent study indicates that probiotic bacteria can 
increase posterior pituitary release of oxytocin and thus circulating 
levels.69 This evidence suggests the possibility of influencing oxytocin 
signaling by targeting gut microbiota. 
Other metabolites 
Significant differences in the plasma levels of several metabolites 
have been reported in studies comparing the plasma metabolomes of 
germ-free and conventional mice, thus underlining the importance of 
intestinal microbiota in the regulation of several metabolic pathways.65 
Further studies are needed to investigate the influence of these 
metabolic imbalances on CNS. 
When comparing ASD children to healthy controls, higher levels of p-
cresol, a phenol compound produced by certain intestinal bacteria and 
probably related to neuropsychiatric impairment, as well as higher 
levels of indole, a precursor of serotonin and melatonin synthesized by 
several commensal bacteria, have been reported.58 The clinical 
relevance of these findings is not known. 
THERAPEUTIC MODULATION OF MICROBIOTA  
Considered the high prevalence of GI disorders in ASD individuals 
and the evidences linking intestinal dysbiosis to GI symptoms and to 
behavioral disturbances in these patients, therapeutic manipulation of 
the intestinal microbiome has been proposed to restore the microbial 
balance in the gut, in order to improve GI and neuropsychiatric 
symptoms. The restoration of a balanced microflora can be targeted 
through the administration of pre- and probiotics, antibiotics, 
nutritional approaches or more recently, through fecal microbiome 
transplantation (FMT).70 
Prebiotics 
The concept of “prebiotic” was firstly introduced in 1995 by Gibson 
and Roberfroid, who defined a prebiotic as “a non-digestible food 
ingredient that beneficially affects the host by selectively stimulating 
the growth and/or activity of one or a limited number of bacteria 
already resident in the colon, and thus improves host health”. At that 
time fructans, comprising fructooligosaccharides (FOS) and inulin, 
and galactans (galactooligosaccharides or GOS) were recognized as 
prebiotics, acting through the enrichment of Lactobacillus and/or 
Bifidobacterium spp. Since then the definition has progressively 
expanded to include additional non-food and non-carbohydrate 
substances with recognized ability to influence gut colonization, as 
well as to consider extra-intestinal effects or applications of prebiotics. 
Thus in 2017 an expert consensus document of the International 
Scientific Association for Probiotics and Prebiotics (ISAPP) released a 
revised definition of prebiotic as “a substrate that is selectively 
utilized by host microorganisms conferring a health benefit”.71 
According to this definition, prebiotics are non-viable substrates that 
serve as nutrients for beneficial microorganisms harbored by the host, 
including administered probiotic strains and resident microbiota. 
Differently from most dietary fibers, which promote growth of a wide 
variety of microorganisms, prebiotics should display a selective effect, 
being substrate for beneficial strains only, thus excluding metabolism 
by pathogenic bacteria such as Clostridium spp and Escherichia coli. 
So far the most studied prebiotics are the non-digestible 
oligosaccharides fructans and galactans, which are mainly found in 
foods like fruit, vegetables, legumes and cereals, cannot be 
metabolized by human gut enzymes, pass across the small bowel 
without being absorbed and reach the colon where they are 
preferentially metabolized by Bifidobacteria. Other substances with a 
recognized prebiotic function are the human milk oligosaccharides 
(HMOs), that are particularly important for the development of the 
intestinal microbiota of the newborn. Consumption of maternal milk 
containing HMOs increases the proportion of intestinal 
Bifidobacteriaceae and Bacteroidaceae.72 Furthermore, fucosylated 
and sialylated HMOs can prevent adhesion of pathogens to the 
intestinal epithelium, thus protecting the baby from infections. Plant 
polyphenols too, although less investigated, are recognized as having 
prebiotic action, particularly after extensive biotransformation by the 
colonic microbiota.71 
As stated in the definition itself, a substance can be considered 
prebiotic if it confers a health benefit to the host. Such benefits are not 
limited to the gut homeostasis but can extend elsewhere in the 
organism, leading to improvements of the immune, metabolic, 
endocrine or nervous functions. Besides enrichment of beneficial 
microbial strains, various other mechanisms have been identified 
through which prebiotics can act: generation of SCFA from their 
bacterial fermentation, elongation of microvilli, increase in mucus 
layer thickness and consequent protection of gut epithelium.71 
At present no clear data are available to demonstrate a role of 
prebiotics in the treatment of autistic patients, although their known 
beneficial effects strongly suggest a potential for their application in 
the management of gut dysbiosis and GI disturbances of ASD 
children.  
Furthermore, an anxiolytic effect of prebiotics has been suggested, 
both in humans and mice models. In human healthy volunteers GOS 
administration has been shown to reduce the cortisol awakening 
response and to modulate some emotional processes.73 The cortisol 
awakening response is a reliable marker of HPA axis activity. 
Prebiotic administration may modulate HPA activity similarly to 
direct administration of probiotic strains in rodents and humans.23, 25, 74  
In 2016 Savignac et al also demonstrated that GOS administration led 
to modulation of cortical IL-1β levels and 5-HT2A receptor 
expression and reduced anxiety behaviors in mice.75 These evidences 
suggest a potential role for prebiotics in ASD and other 
neuropsychiatric disorders where anxiety and neuroinflammation are 
prominent clinical features. 
Recent studies demonstrated an influence of prebiotic administration 
on central Brain Derived Neurotrophic Factor (BDNF) expression. 
BDNF is important for survival and differentiation of dopaminergic 
neurons in the developing brain, regulates the formation and plasticity 
of synaptic connections and is also trophic for serotonergic neurons. 
Impairment in BDNF signaling in early developmental phases is 
thought to be related to CNS abnormalities, severer forms of autism 
and intellectual disability, as well as epileptic manifestations. Studies 
in autistic patients reported conflicting data about BDNF levels, 
showing often higher, but sometimes lower or not significantly 
different levels compared to controls.76 In GF rodents the central 
expression of BDNF and N-methyl-d-aspartate receptor (NMDAR) 
subunits is reduced, whereas administration of oral probiotics is 
known to increase BDNF levels. In 2013 Savignac et al demonstrated 
that prebiotic feeding too elevates hippocampal BDNF and NMDAR 
subunits expression in rats, confirming a role of gut microbiota in 
regulating BDNF synthesis.62 These preliminary results warrant 
further investigation to better understand the role of BDNF in autism 
pathogenesis and the potential usefulness of its modulation through 
pre and probiotic administration in early life.  
Further investigations are needed to ascertain the beneficial 
neurotropic effects of prebiotics, particularly in ASD individuals.  
Probiotics 
According to the Food and Agriculture Organization (FAO)/World 
Health Organization (WHO) definition of 2001, probiotics are 
products that contain live microorganisms, which have beneficial and 
desirable effects on humans and animals when provided in adequate 
amounts.  
As previously observed, several data suggest that probiotic 
administration can not only reverse gut dysbiosis and relieve GI 
disturbances, but also exert central actions, promoting positive 
behavioral changes both in animal models and humans with or without 
ASD.19, 21, 25, 77-81 Probiotic intake has been linked to reduced 
subjective feelings of anxiety and improved well-being.74, 82 For 
instance, the administration of Lactobacillus helveticus and 
Bifidobacterium longum reduced anxiety-like behaviors in rats and 
relieved psychological distress in healthy humans.74 Another study 
showed that administration of a 4-week course of a multispecies 
probiotic containing B. bifidum, B. lactis, L. acidophilus, L. brevis, L. 
casei, L. salivarius and L. lactis decreased cognitive reactivity to sad 
mood and aggressive thoughts in humans.83 Furthermore, a functional 
MRI investigation revealed that administration of a fermented milk 
product with probiotics resulted in measurable changes in emotional 
processing in the healthy human brain.84 
In rats, the oral administration of Bifidobacteria increased levels of 
hippocampal BDNF, which plays an important role in 
neurodevelopment and may also exert some antidepressant actions.85 
Similarly, L. reuteri administration has been showed to elevate 
oxytocin levels, a key regulator of social behaviours.86 Finally, as 
mentioned before, probiotic therapy could lead to a modulation of the 
HPA axis functioning and regulation of the cortisol stress response, as 
well as to a down-regulation of inflammatory pathways in the gut and 
CNS.25 
In 2015 a randomized trial showed that early postnatal probiotic 
treatment decreases ASD risk. The enrolled children were randomly 
assigned to the probiotic or placebo groups during the first six months 
of life and results showed that none in the probiotic and 17% in the 
placebo group was diagnosed with ASD or ADHD.87 The authors 
noted that no significant modification of the microbiota composition 
was determined by probiotic therapy in their cohort, thus suggesting 
that the central effects of probiotics are likely mediated by other 
mechanisms such as reduced inflammatory milieu, reduced gut 
permeability, strengthened BBB, restoration of a normal balance 
between harmful and beneficial gut bacterial products. 
Antibiotics 
Further support for the hypothesis of a microbiota-gut-brain axis 
comes from studies on autistic children who were treated with 
antibiotics. A subgroup of autistic children appears to develop 
normally until a cognitive deterioration is observed. In some cases the 
onset of these regressive forms of autism is preceded by antibiotic 
exposure and chronic diarrhea reported by parents. Consequently, a 
potential pathogenetic role of certain antibiotics has been postulated, 
as they could dysregulate intestinal microflora, promoting gut 
colonization by neurotoxin-producing bacteria, such as Clostridium 
spp, resulting in disruption of neurodevelopmental processes.88 
Specifically, a correlation between the use of broad-spectrum 
antibiotics, such as amoxicillin-clavulanate, and ASD onset has been 
noticed. The increased incidence of middle ear infections in ASD 
children, together with the extensive use of broad-spectrum antibiotics 
in contemporary society, have been advocated as possible causes of 
the recent increases in ASD epidemiology. 
A trial with 8-week oral vancomycin administration in a small group 
of children with regressive-onset autism determined a transient but 
significant improvement in both GI and behavioral disturbances.88 
Indeed vancomycin is a minimally absorbed antibiotic, active against 
Clostridia, and its antibacterial activity can explain the observed 
benefits as a consequence of the modulation of the gut microbiota. 
The symptomatic relapse after therapy discontinuation could be linked 
to the conversion of Clostridia to a spore-form, highly resistant to 
antibiotics, which can later newly germinate into vital forms.  
Extensive and prolonged use of vancomycin or other antibiotics is 
therefore not advisable, because of the risk of selecting resistant 
strains.  
Fecal Microbiota Transplantation (FMT) 
The process of FMT consists in the delivery of feces from a donor to a 
recipient, with the aim of replacing an impaired microbiota with a 
healthy one.  
A Chinese physician, Ge Hong, described the use of FMT in human 
medicine for the first time approximately 1700 years ago for treating 
severe diarrhea. In 1958 FMT has been introduced in modern 
medicine for the management of antibiotic-associated 
pseudomembranous enterocolitis.  Recently, in several randomized 
clinical trials FMT demonstrated its efficacy in treating antibiotic-
refractory C. difficile infection, a severe life-threatening condition.89, 
90 
Currently, interest about the use of FMT as a therapeutic strategy for 
diseases related to gut dysbiosis has grown. Unlike probiotics, which 
contain only a restricted number of bacterial species, FMT allows the 
transplantation of thousands of different components of the healthy 
gut microbiota, resulting therefore a promising therapeutic approach 
for GI diseases such as inflammatory bowel diseases, irritable bowel 
syndrome and chronic constipation, and non-GI diseases like 
autoimmune disorders, obesity and insulin sensitivity. Moreover, it is 
a safe and well-tolerated treatment: the most commonly reported 
adverse events include mild diarrhea, abdominal tenderness, bloating, 
flatulence and nausea.89 
Since, as previously explained, ASD subjects often display dysbiosis, 
FMT can be considered a potential therapeutic intervention for these 
patients, thanks to its ability to revert gut microbiota abnormalities.91 
Recently, Kang et al. published an open-label study investigating 
safety, tolerability and efficacy of FMT in autistic patients. The study 
involved 18 ASD patients with GI symptoms and a control group of 
20 neurotypical subjects. ASD patients underwent a modified FMT 
protocol, named Microbiota Transfer Therapy: oral vancomycin 
treatment, followed by laxatives administration and a subsequent high 
initial dose of Standardized Human Gut Microbiota-SHGM (orally or 
rectally). Afterwards, a daily lower maintenance oral dose of SHGM 
associated to proton pump inhibitors (PPI) was given for 7-8 weeks. 
Patients in the control group did not receive any therapeutic 
intervention. GI and ASD-related symptoms improved in the 
treatment group, with response maintenance during follow-up. FMT 
confirmed its ability in modifying gut microbiota composition: levels 
of Bifidobacteria, Prevotella and Desulfovibrio significantly 
increased. In line with previous reports, few adverse events were 
described, thus confirming treatment safety also in autistic patients.92 
According to these results, FMT can be considered an effective and 
well-tolerated approach in ASD. However, the study was neither 
blinded nor placebo controlled. Hence, the amelioration of GI and 
ASD–related symptoms should be carefully interpreted as it could 
derive from placebo effect. Moreover, it described the effects of four 
combined treatments, and it has to be determined if these results 
derive solely from one of the elements (vancomycin, laxatives, 
SHGM, PPI) or from their combination.  
In conclusion, results are promising, but randomized, placebo-
controlled, double blinded studies are needed to confirm these 
outcomes. A larger sample size and a longer follow-up period will be 
essential to clarify long-term safety and tolerability, particularly to 
clear up concerns about the potential risk of transmission of 
pathogenic agents or the possible epigenetic influences on human 
genoma over time. 
Diet 
In recent years research focusing on nutritional approaches in autism 
has increased. The rising interest on the potential role of dietary 
interventions in ASD originates from three main elements.  
First, ASD patients are more frequently selective eaters then 
neurotypical children of the same age. Indeed, they usually display 
restricted diets, with a limited food repertoire, resulting in reduced 
fruit, vegetables and protein intake. Kanner firstly described feeding 
difficulties in autistic patients in 1943: “Our patients, anxious to keep 
the outside world away, indicated this by the refusal of food”.  
Second, some reports showed improvement of ASD symptoms after 
specific dietary changes. Third, diet highly influences gut microbiota 
composition, thus suggesting that a rebalance in intestinal microbiota 
induced by diet could explain symptoms amelioration.  
So far, several dietary interventions have been described in ASD: 
ketogenic diet, gluten-free casein-free (GF/CF) diet, ω-3 fatty acids, 
digestive enzymes or vitamins supplementation, consumption of 
curcumin or camel milk.93 
Below, we discuss in detail the most relevant nutritional approaches 
investigated in autistic patients.  
 
Ketogenic Diet (KD) 
KD is a nutritional regimen very low in carbohydrates, high in fat and 
with an adequate proportion of proteins. KD causes a metabolism 
shift, mimicking the fasting state and resulting in higher synthesis of 
ketone bodies. It is commonly used in pediatric neurology owing to its 
effectiveness in treating drug-resistant epilepsy, even though its exact 
mechanism of action remains unclear. Modification of gut microbiota 
composition after the KD has been described in several studies in 
neurologic patients.94  
In animal models of ASD, both improvement of behavioral symptoms 
and compositional remodeling of gut microbiota after KD have been 
described.93, 95 
In humans, several case reports evidenced a potential role of KD in 
ameliorating autistic symptoms. Two non placebo-controlled studies 
were conducted (recruiting respectively 30 and 15 patients), both 
confirming the beneficial effects of KD in autistic patients.96, 97 
Further studies are required to confirm these preliminary data and to 
analyze the possible impact of KD on autistic behavior. 
Gluten-Free Casein-Free Diet (GF/CF) 
Hans Asperger was the first one to suggest a potential relationship 
between autism and celiac disease in 1961, paving the way for 
attempting gluten-free nutritional interventions in ASD patients. 
Afterwards, theories enlightening the potential harmful effect of diets 
containing gluten and casein in autistic patients developed. According 
to these theories, ASD pathogenesis could be explained, at least in 
part, by an excess of opioid activity in the CNS. As stated by these 
models, a reduced activity of peptidase enzymes results in gluten and 
casein abnormal metabolism, with an excessive production of 
incompletely metabolized peptides. These peptides, thanks to the 
increased  permeability of the intestinal and blood-brain barriers, can 
enter the bloodstream and reach the CNS. Here, they can act like 
opioid neurotransmitters or interfere with the hydrolysis of other 
neurotransmitters binding central peptidase enzymes, halting their 
metabolic activity. Furthermore, gluten and casein peptides have been 
suggested to unbalance the immune response, triggering local 
inflammation, thus enhancing the increased intestinal permeability, 
and also promoting systemic cytokine synthesis.93 
Both excessive central opioid activity and unbalanced inflammatory 
response can adversely affect CNS development and function. 
Consequently, the GF/CF diet was proposed as a possible therapeutic 
approach for patients with ASD. 
In 1995, a non-randomized, non-blinded study by Knivsberg et al., 
conducted on 15 ASD patients, showed a potential benefit of GF/CF 
diet on autistic-related behaviors. These results added scientific 
significance to the great number of previous anecdotal observations.  
Subsequently, numerous research studies worldwide, including 
randomized clinical trials (RCT), have examined the role of GF/CF 
diet in autism, and several systematic reviews have been published.  
When analyzing these studies, many methodological issues stand out: 
a lack of placebo in some trials, small sample sizes, wide age ranges, 
short duration and follow up, concomitant administration of other 
therapies, difficult assessment of dietary adherence and outcomes 
(mostly based on parental observations). 
Moreover, results about the efficacy of GF/CF diet on behavioral 
symptoms are conflicting and often not statistically significant. At the 
moment, the limited available data suggest that there is no sufficient 
evidence to support the adoption of GF/CF diet in ASD children. 
These results have to be carefully interpreted, as the number of high 
quality studies is limited to draw a clear conclusion; therefore, the 
need for further research has to be stressed.93, 98 
 
ω -3 fatty acid supplementation 
ω-3 fatty acids are essential fatty acids, considered to be fundamental 
for a balanced and physiological neurodevelopment. Indeed, 
deficiency in ω-3 fatty acids has been described in different 
psychiatric disorders, including ASD.  
Therefore, several studies were conducted to analyze behavioral 
improvement in autistic children after dietary supplementation of ω-3 
fatty acids.  
Case control and open label studies initially provided evidence of a 
potential efficacy of ω-3 fatty acids, whereas RCT yielded contrasting 
and heterogeneous outcomes. Administered doses were highly 
dissimilar among different studies, with often limited sample size. On 
the basis of current evidence, ω-3 fatty acids could be used as a 
complementary therapy in ASD, but their effect on ASD symptoms 
has still to be clarified.99 
 
Digestive enzymes supplementation 
Deficiency in digestive enzymes has been described in ASD patients, 
in particular a lack in those responsible for carbohydrate digestion. 89 
Therefore, undigested elements can be used as a source of energy for 
intestinal bacteria, potentially contributing to gut dysbiosis. 
Hence, digestive enzymes supplementation has been tested as a 
possible therapy for autistic children. A first pilot, non placebo-
controlled study showed an improvement in behavioral disturbances in 
ASD patients after enzymes administration. This evidence was not 
confirmed in a subsequent randomized placebo-controlled clinical 
trial. 89 
It should be noted, however, that this two studies cannot be properly 
compared, as they used different enzymes formula. In the first case a 
mixture of enzymes digesting both carbohydrates and proteins was 
used, whilst in the RCT only proteolytic enzymes were administered. 
We may argue that failure to demonstrate a beneficial effect of 
enzyme supplementation in the RCT might have been determined by 
the absence of glycolytic enzymes. According to these partial and 
preliminary results, the matter remains an interesting area of research, 
which deserves further investigations.89 
 
Vitamins supplementation 
Vitamins are essential for our organism homeostasis and, as 
previously said, several of them can be synthetized by gut microbiota, 
such as biotin and vitamin K. Various vitamin deficiencies have been 
described in ASD patients, generating a wider interest in the possible 
efficacy of their supplementation as a therapeutic approach. For 
instance recent studies highlighted the possible role of vitamin D 
deficiency in ASD, as it is frequently described in autistic patients and 
a maternal deficit during pregnancy has been linked to a higher risk of 
autism in the newborn. 
In a placebo-controlled study conducted by Adams et al., a 
formulation of vitamins and minerals, including vitamin K and biotin, 
was administered to autistic patients for 3 months. After 
supplementation, a behavioral improvement was demonstrated. 
Regression analysis showed that low pre-treatment levels of biotin and 
vitamin K were highly related to symptoms amelioration, thus being 
the best predictors of improvement.100 
In conclusion, autistic patients may commonly have hypovitaminosis, 
partly due to a lower GI microbial synthesis, partly due to a reduced 
intake; so we can hypothesize that vitamins supplementation could be 
beneficial in these patients. Further research is needed. 
 
Curcumin  
Curcumin has been used for centuries in traditional medicine. 
Recently, interest concerning the use of curcumin has raised, as a 
consequence of growing evidences of its anti-inflammatory, 
antioxidant, neuroprotective and monoaminergic effects. In murine 
models of ASD, curcumin administration over a period of 4 weeks 
improved ASD-related symptoms, namely restoring social interactions 
and reducing anxiety and repetitive behaviors. 
Studies on humans have yet to be conducted, but curcumin could be a 
promising therapeutic approach in these patients. 89 
 
Camel milk 
Camel’s milk has a unique composition: compared to cow’s milk, it 
contains more minerals, more vitamins, less fat and less lactose; it 
lacks of β-lactoglobulin and β-casein, potentially allergenic, and 
contains various components with antibacterial and immunological 
properties. Furthermore, it may, at least in part, influence gut 
microbiota composition owing to its content of bacteria and prebiotics. 
A first study by Al-Ayadhi et al. displayed a potential benefit of 
camel’s milk compared to cow’s milk: in the treatment group, ASD 
symptoms improved and oxidative stress decreased, as demonstrated 
by an increase in plasma levels of superoxide dismutase, 
myeloperoxidase and gluthatione. Behavioral improvement induced 
by camel’s milk was confirmed by two subsequent studies. It should 
be noted that the use of cow’s milk as a control could be a potential 
confounder, as it is believed to stimulate the immune function and 
increase the oxidative stress. 89 
Further studies are requested to confirm the potential efficacy of this 
dietary intervention, better if not using cow’s milk as a control, in 
order to clarify whether the observed effects are merely due to the lack 
of cow’s milk in the diet or to a specific effect of camel’s milk.  
No evidence about the effectiveness of other nutritional approaches, 
such as low FODMAP (Fermentable Oligosaccharides, Disaccharides, 
Monosaccharides and Polyiols) diets or food additives exclusion diets 
in ASD exists.  
Generally speaking, we can argue that very little is known about the 
impact of dietary interventions on symptoms and microbiota 
composition in ASD patients. Unfortunately, available data are limited 
and frequently contradictory. Furthermore, the risk of provoking 
nutritional deficiencies in developing children as well as the risk of 
low adherence, require additional attention when introducing diet 
changes in our patients, carefully balancing risks and benefits. Well-
designed clinical trials, focusing on the consequences of dietary 
interventions on symptoms, gut microbiota composition and 
nutritional state in autistic patients are required. 
 
CONCLUSION 
In recent years the increased prevalence of autism spectrum disorders, 
along with the evidence of a significant link between autism and GI 
disturbances, raised a special interest in exploring the reciprocal 
influences between gut and brain in ASD. At the same time, 
investigators highlighted the existence of a so-called “gut-brain axis”, 
empowering the hypothesis that symptoms of neuropsychiatric 
disorders, like ASD, could be triggered by GI abnormalities. Intestinal 
microbiota is thought to play a pivotal role in gut and systemic 
homeostasis, in CNS development, as well as in behavioral 
modulation. In most studies comparing ASD children versus healthy 
peers, significant differences in microbiota composition have been 
identified, mainly consisting in reduced levels of Bifidobacter and 
increased levels of Clostridium spp and Desulfovibrio. It is still a 
matter of debate if these microbial imbalances can be primarily 
involved in ASD pathogenesis or if they are just a consequence of 
dietary dysregulation, a common issue in autistic children. However 
consistent data, mainly in animal models, suggest a strong potential 
for dysbiosis to induce alterations in CNS development and 
functioning. On the basis of the actual knowledge, it can be postulated 
that a dysregulated microbiota could generate a negative environment, 
able to disrupt the physiological neurodevelopment. Multiple factors 
could be involved in unbalancing this process: the bacterial production 
of neurotoxic compounds, whose absorption can be fostered by the 
presence of a leaky gut; the induction of a pro-inflammatory milieu, 
stimulating itself the HPA axis and amplifying stress response; the 
impairment in protective SCFA generation; the imbalances in 
neurotransmitters synthesis and signaling; the alteration of oxytocin 
release. 
In accordance with these findings, studies analyzing the modulation of 
intestinal microbiota through different approaches (administration of 
pre- and probiotics, antibiotics, FMT, special diets) show promising 
results in relieving some autistic disturbances mainly in animal 
models but also in humans. At present robust data are lacking and no 
clear recommendation can be made concerning the use of such 
therapeutic interventions in ASD patients. In the near future new well-
designed trials are awaited, investigating the role of dysbiosis and its 
correction on larger populations of ASD patients. 
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